Novo Holdings Cyma Bay Therapeutics, Inc. Transaction History

Novo Holdings

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $8.42 Million - $16.3 Million	-666,521 Reduced 42.55%	900,000 $21.3 Million
Q3 2023 Nov 14, 2023	SELL	$10.86 - $17.62 $4.71 Million - $7.64 Million	-433,479 Reduced 21.67%	1,566,521 $23.4 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $14.9 Million - $21.9 Million	2,000,000 New	2,000,000 $21.9 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

Stay updated on Novo Holdings with notifications on news.